EPO published Takeda Pharmaceutical's patent application EP4208474A2 for interleukin-2 muteins and their uses. The patent covers modified IL-2 protein compositions (C07K 14/47) with therapeutic applications including immune modulation (A61P 37/00) and potential cancer immunotherapy uses. Six inventors are listed: Miyakawa, Warude, Shaw, Kim, Eryilmaz, and Sato. The application designates 32 European Contracting States including Germany, France, UK, Italy, Spain, and the Nordic countries.

Pharmaceutical companies developing IL-2 based therapeutics or biosimilars should review this patent for potential freedom-to-operate concerns. Generic and biosimilar manufacturers should assess whether their development programs may infringe on Takeda's claimed mutein compositions. Licensing negotiations may be warranted for parties seeking to commercialize competing IL-2 mutein products in designated European territories.